Semax

Overview

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been registered as a pharmaceutical drug in Russia since 1994, where it is used for stroke, TBI, and cognitive enhancement. It is a modification of the ACTH(4-7) fragment with added Pro-Gly-Pro to increase stability and improve CNS penetration.

Semaxhas demonstrated upregulation of BDNF and its receptor TrkB in the hippocampus and other brain regions, along with neuroprotective effects in ischemia models. It also modulates the dopamine and serotonin systems. Its intranasal bioavailability, safety record in Russia, and cognitive effects have made it among the most studied nootropic peptides in the research literature.

Mechanism of Action

Semax acts partly through melanocortin receptors (MC4R) and partly through direct enhancement of BDNF/TrkB signaling. It increases synaptic plasticity-related gene expression and protects neurons from glutamate-induced excitotoxicity. It may also modulate the dopaminergic and serotonergic neurotransmitter systems in ways that promote focus, memory consolidation, and mood.

Research Areas

• ●Ischemic stroke neuroprotection
• ●BDNF upregulation and neuroplasticity
• ●Attention, learning, and memory in rodents
• ●Anxiety and stress resilience
• ●Optic nerve and vision research
• ●ADHD-related concentration research

Storage & Handling

For Research Use Only. This information is provided for educational and research purposes. Semax is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.